Ken Griffin Cybin Inc. Transaction History

Citadel Advisors LLC

  • $618 Billion
  • Q3 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.3 - $0.56 $75,376 - $140,703
251,256 Added 203.78%
374,553 $142,000
Q4 2022

Feb 14, 2023
BUY
$0.26 - $0.64 $32,057 - $78,910
123,297 New
123,297 $36,000

About CYBIN INC.

CYBN Quotes by TradingView
  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $985M
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email